Open    Access



Al-Akidi Therapeutic Protocol for Severe Infections Associated with Covid-19: Potential and Effective Treatment by Levofloxacin and Vitamin D3 and Zinc (Part 1)



Author(s)

Shakir Mahmood Alwan

Full-Text PDF XML     529 Views

DOI:10.17265/2328-2150/2022.04.001

Background: The emergence of Coronavirus SARS-CoV-2 evoked an unprecedented threat globally. Ever since the spread of this pandemic research and clinical trials have concentrated on the repurposing of already exciting FDA drugs to find a successful candidate to combat Covid-19. Objective: The objective of this study is to propose a therapeutic protocol that may have a potential solution to treat the severe infections associated with coronavirus. The clinical application of this protocol (Al-Akidi Therapeutic Protocol, A-TP) is highly recommended, as there are several scientific evidences that support this trusted protocol to be of great potential. Methods and Materials: This A-TP includes the use of one of the respiratory Fluoroquinolones (Levofloxacin or Moxifloxacin) in doses of 500 mg twice daily for 7-10 days, together with high doses of Vitamin D3 (10000 IU/day) and Zinc (50 mg daily) for few weeks. This protocol is based on the previous antiviral activity of those Fluoroquinolones towards few viruses, the potent antibacterial activity on respiratory infections and high available concentrations in the lungs. It is also based on molecular docking of Levofloxacin and Moxifloxacin on various viral enzymes. Results: Molecular docking showed encouraging and very interesting docking scores and binding affinity of Levofloxacin and Moxifloxacin to certain viral enzymes, such as, RNA dependent RNA polymerase (RdRp), 3-Cysteine-Likeprotease, Neuraminidase, Replicase polyproteins and Trans-Membrane Protease Serine 2 inhibitor (TMPRSS2). The highly expected clinical results of using this protocol are; reduce infection, control of temperature, improve breathing with less dependent on supplemented oxygen, and remarkable reduction of the pro-inflammatory cytokine storm, and hence, reduce hospitalization and mortality. Conclusion: Levofloxacin is highly recommended in managing the severe infections associated with Corona virus and has a remarkable reduction of pro-inflammatory cytokine storm as an immuomodulating agent. Levofloxacin is superior in this protocol over Moxifloxacin, due to its high excretion (≤ 83%) as unchanged through the kidneys, while Moxifloxacin is only 20% is excreted unchanged. It is an extra advantage of Levofloxacin to manage coronavirus in the kidneys. High doses of Vitamin D3 and Zinc are very useful to provide additional effective measures to combat Corona virus. Therefore, the use of this A-TP is highly and strongly recommended, as it serves the full requirements for excellent and potential therapy for the severe infections associated with Covid-19.

Covid-19, Levofloxacin, Moxifloxacin, ACE2, docking, protocol, viral enzymes, 3CL pro-1, Camostat, Panobinostat, Oseltamivir acid.

Alwan, S. M. 2022. "Al-Akidi Therapeutic Protocol for Severe Infections Associated with Covid-19: Potential and Effective Treatment by Levofloxacin and Vitamin D3 and Zinc (Part 1)​." Journal of Pharmacy and Pharmacology 10 (4): 105-119.